Turning Point Brands has supplied $15m for cannabinoid health product developer Dosist through a co-development and distribution pact.
Dosist, a US-based provider of cannabinoid health products, has received $15m from Turning Point Brands (TPB), a New York-listed branded consumer products manufacturer.
Founded in 2016, Dosist has developed internationally patented dose-control inhalation technology for cannabidiol (CBD) and THC ingredients found in cannabis. It raised an undisclosed amount of series A funding from venture capital firm Plus Capital in September 2018.
The investment comes with an agreement that TPB will get exclusive co-development and distribution rights to a new…
